Type2 Diabetes Mellitus
Conditions
Brief summary
The objective of this clinical study is to compare the pharmacokinetics and the safety between a fixed-dose combination administration of BR3005 and co-administration of BR3005-1 and BR3005-2 under fed conditions in healthy adult volunteers
Interventions
Sponsors
Boryung Pharmaceutical Co., Ltd
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Those who have body mass index (BMI) within the range of 18.0 to 30.0kg/m² at screening visit * In case of a male subject, Those who weigh 50 kg or more * In case of a female subject, Those who weigh 45 kg or more * Those who sign written consent spontaneously after listening to and understanding sufficient explanation of the purpose and contents of this clinical trial, characteristics of the Investigational products, expected adverse events, etc.
Exclusion criteria
* Those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 30 days prior to the first day of administration or have taken drugs concerned about affecting this clinical trial within 10 days prior to the first day of administration. (however, participation is possible considering pharmacokinetics and pharmacodynamics such as Interaction of investigational products, half-life of concomitant drugs, etc.) * Those who have participated in other clinical trials(including bioequivalence tests) and administered their investigational products within 6 months prior to the first administration date.(However, the termination for participation in other clinical trials are based on the last administration date of their investigational products) * Those who have a medical history of gastrointestinal surgery or gastrointestinal diseases that may affect the absorption of drugs. (Except for simple appendectomy, hernia surgery) * In the case of a female subject, those suspected pregnancy, pregnant woman, lactating woman.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUCτ | 0~48 hours after administration | Area under the Plasma Concentration-Time Curve During a Dosing Interval (tau) |
| Cmax | 0~48 hours after administration | Maximum Concentration of Drug in Plasma |
Countries
South Korea
Outcome results
None listed